Other alternative is to position CIMAvax-EGF in combination with pembrolizumab or atezolizumab, as starting therapy in stage IV NSCLC with 50% overexpression of PD-L1, irrespective of histology (Table 3). The gene discussed is CD274; the disease is non-small cell lung carcinoma.